Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation
Journal
Journal of cardiology
Journal Volume
74
Journal Issue
4
Pages
372
Date Issued
2019-10
Author(s)
Chang, Hung-Yu
Feng, An-Ning
Fong, Man-Cai
Hsueh, Chao-Wen
Lai, Wei-Tsung
Chong, Eric
Chen, Chi-Nan
Chang, Hung-Chuan
Yin, Wei-Hsian
Abstract
Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to reduce cardiovascular mortality by 20% as compared with enalapril in a randomized controlled trial. However, there is a paucity of real-world data on the effects of ARNI in heart failure patients with reduced ejection fraction (HFrEF), especially those with concurrent renal impairment or hypotension.
Subjects
Chronic kidney disease; Heart failure; Sacubitril/valsartan
Type
journal article